Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Capricor is planning to start an application seeking the FDA's approval of deramiocel for DMD-related heart disease.

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

With the recipient facing extreme breathing difficulty, a heart transplant was the only option left. While his family waited ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

4 Treatment is supportive and guided by hemodynamics and the presence of left ventricular outflow tract obstruction Treatment of hemodynamically stable patients follows standard guidelines for ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...

Cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated ... including assessment of LVEF at baseline and during treatment. For patients receiving TAGRISSO in combination with pemetrexed and ...

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...